Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Epratuzumab Y-90 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms RITEPRALL
- 17 Jan 2017 Planned End Date changed from 1 Sep 2020 to 1 Jan 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 Sep 2020 to 1 Jan 2017.
- 17 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.